News & Press

Press Releases

Addressing patient needs through scientific driven innovation

We aspire to become a leading biopharmaceutical company that discovers and develops novel, differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and worldwide.

Press Releases
Abbisko and Allist Pharmaceuticals Jointly Announce the Initiation of a Phase 2 Clinical Study Evaluating oral PD-L1 small molecule ABSK043 in Combination with Furmonertinib Mesylate Tablets for the Treatment of Advanced Non-Small Cell Lung Cancer
May 09, 2024
Abbisko Therapeutics Announces Irpagratinib, an Innovative FGFR4 inhibitor,has been Granted ODD by the U.S. FDA for the Treatment of HCC
Apr 25, 2024
2024 AACR | Abbisko Therapeutics Presented 3 Pre-clinical Research Results with Oral and Poster Presentations
Apr 10, 2024
Abbisko Therapeutics Completes Dosing of the First Patient in the Phase II Clinical Trial for ABSK011 in Combination with an Anti-PD-L1 Antibody
Feb 08, 2022
View all
we discover and develop first-in-class and best-in-class therapies
to address critical unmet needs for cancer patients in China and globally
Media
Bioworld: Abbisko out-licenses pimicotinib to Merck KGaA in $605M deal
Dec 12, 2023
Endpoints: Abbisko signs $70M upfront deal with Merck KGaA for PhIII cancer drug
Dec 05, 2023
FierceBiotech:Merck KGaA buys into Abbisko’s late-stage joint tumor med for $70M upfront
Dec 05, 2023
View all

Tel:(+86) 021-68912098

E-Mail:Bd@abbisko.com
    PR@abbisko.com
    IR@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号-1    PRIVACY POLICY